Clinical Trials Browser

Lymphoma, Non-Hodgkin × Brentuximab Vedotin × 30 days × Clear all

NCT01703949 2026-05-12

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

28 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin